CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Image credit: Shutterstock / CI Photos. US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global rights to a ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price target to HK$57.67. Discover the latest stocks ...

WuXi Biologics (HKEX: 2269) has signed a deal with Sino Biopharm (HKEX: 1177) to develop a first-in-class monoclonal antibody targeting an undisclosed indication. The firm will provide integrated ...

Masayoshi Ōishi, Ayaka Nanase Perform New Themes for Yu-Gi-Oh! Go Rush!! Anime (Mar 18, 2024) Yu-Gi-Oh! Go Rush!! Anime Enters into 3rd Year in April 2024, Reveals New Visual (Dec 16, 2023) Yu-Gi ...

Roche, which put billions on the line a year ago across several ADC pacts, has returned to Innovent Biologics—this time delving into the China-based biopharma’s pipeline for IBI3009 ...